English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Whether sex can influence the clinical response to biologic treatment in severe asthma patients has not been fully addressed. The aim of this study was to investigate in severe asthma patients undergoing biologic treatment the individual evolution of lung function measurements and patient reported asthma control scores over a twelve-months follow-up period, in relation to patients’ sex, in different age ranges. Secondly, the change in the administered dose of oral corticosteroids (OCS) before and after twelve-months treatment was investigated. Overall 64 patients (58% females and 42% males) with a median age of 52 years were enrolled in the study. No relevant differences in terms of lung function, patient reported asthma control, exacerbation rate and daily OCS dose were observed by gender within the study timeframe. A separate sub-analysis by biologic treatment, confirmed the same finding. Stratifying individuals by age, we showed that elderly men resulted in lower lung function parameters’ values (FEV1% predicted and FEV1/FVC index) when compared to elderly women, whereas an opposite trend was observed in terms of ACT score. No other relevant differences were detected after age-stratification. According to our findings gender seems not to act as a determinant of treatment response to biologics in severe asthmatics. Although to be confirmed in larger studies, our data suggest that neither gender nor age of patients should limit the biologic treatment prescription, once that the eligibility criteria for that therapy are satisfied.

Clinical response to biologics for severe asthma: any relevance for sex in different age ranges?